ABSTRACT: Trials were conducted with beef heifers at 4 sites to evaluate feedlot performance and carcass characteristics in response to implants containing 14 mg estradiol benzoate and 100 mg trenbolone acetate (EB/ TBA; Synovex Choice, Zoetis LLC, New York, NY), 14 mg estradiol benzoate (EB), 100 mg trenbolone acetate (TBA), or a sham-implanted control (SC). The study design at each site was a randomized complete block with 12 blocks and 4 treatments. Blocks of cattle at each site were harvested in commercial abattoirs when masked personnel estimated at least 60% of animals would yield carcasses with USDA quality grades of Choice or Prime. Data were pooled across sites for statistical analysis. Initial BW averaged 374 kg, and days on feed ranged from 98 to 126 d (mean 112 d). Heifers implanted with EB/TBA, EB, and TBA had greater ADG and G:F (P < 0.05) than SC; ADG and G:F were greater for EB/TBA than EB or TBA (P < 0.05). Heifers treated with TBA had greater G:F than EB (P < 0.05). Feed intake was not affected by treatments. Mean HCW and LM area for EB/TBA were greater than for other treatments (P < 0.05). Mean HCW for TBA was greater than SC (P < 0.05) but not different from EB. Mean LM area for EB and TBA were greater than SC (P < 0.05) but not different from each other. There were no treatment differences (P > 0.05) for KPH, 12th-rib fat thickness, or yield grade. Dressing percent was greater for EB/TBA than SC (P < 0.05) but not different from EB or TBA. Marbling score was decreased by EB/TBA (P < 0.05) compared with other treatments, but no other differences were noted. Despite the effect of EB/ TBA on marbling scores, there were no signifi cant (P > 0.05) treatment differences on proportions of carcasses with quality grades ≥ Choice vs. < Choice. With respect to ADG and G:F, implants containing EB, TBA, or EB/TBA produced improved responses over SC. Furthermore, EB/ TBA induced greater ADG and G:F responses than EB and TBA. Results confi rmed that EB and TBA have additive effects, as evidenced by the observation that calves implanted with EB/TBA had signifi cantly greater ADG and G:F than heifers implanted with either EB or TBA alone or compared with SC heifers.
INTRODUCTION
A previous report demonstrated that feedlot steers and heifers responded to implants that contained 28 mg estradiol benzoate (EB) and 200 mg trenbolone acetate (TBA; Synovex Plus, Zoetis LLC, Madison NJ) with improved feedlot performance compared with nontreated controls (Herschler et al., 1995) . Furthermore, studies showed that both EB and TBA contributed to performance responses in feedlot steers (Herschler et al., 1995) and heifers (Cleale et al., 1999) after treatment with Synovex Plus. The fact that estrogens and androgens have additive or synergistic effects is likely related to their different putative mechanisms of action (Hayden et al., 1992) . Beef cattle growth studies suggest that responses to estrogens are primarily mediated by effects on pituitary GH secretion (Grigsby and Trenkle, 1986; Johnson et al., 1996) . In contrast, the mechanism of action of TBA appears related to downregulation of cortisol to mitigate its antianabolic effects (Hayden et al., 1992; Isaacson et al., 1993) .
Synovex Choice (Zoetis LLC; EB/TBA) is a growth-promoting implant that contains 14 mg EB and 100 mg TBA per dose, one-half the amount of active ingredients in Synovex Plus. This product is approved for use in steers fed in confi nement for slaughter in several countries and for both steers and heifers in Canada. Objectives of the multisite study we report here were to determine if EB/TBA could stimulate increases in growth performance measurements, especially ADG and G:F, in feedlot heifers compared with a sham-implanted control treatment and also compared with heifers implanted with 14 mg EB but no TBA or no EB and 100 mg TBA.
MATERIALS AND METHODS
Trials were conducted in cattle feedlot facilities under routine management practices in accordance with 7 U.S.C. 54.
At each of 4 locations (ID, TX, KS, and CO), studies were conducted with English and Continental beef-type heifers (initial BW = 374 kg) to evaluate feedlot performance when treated as sham-implanted negative controls (SC), with a single implant that contained 14 mg EB and 0 mg TBA (EB), with a single implant that contained 0 mg EB and 100 mg TBA (TBA), or with the commercial product containing 14 mg EB and 100 mg TBA per dose (EB/TBA). Trials at ID, TX, and CO used pens containing 10 animals each (120 per treatment), whereas the KS trial utilized pens containing 8 animals each (96 per treatment). Each study site used a randomized complete block experimental design. Available heifers at each site were sorted on the basis of BW measured 2 to 3 d before treatment. Heavy, light, and ill animals were excluded from consideration for study enrollment, and then remaining heifers were divided into 12 strata (blocks); animals within blocks were randomly assigned to the 4 treatments. Thus, each trial site utilized 48 pens of cattle and 12 pens per treatment. Trials began between October 2008 and January 2009, and harvests occurred between February and May 2009.
Cattle acquired for studies were received at feedlots at least 14 d before treatment administration to allow time to acclimate to study facilities. Incoming cattle were processed according to procedures typical of the beef-feeding industry, which minimally included vaccinations against respiratory pathogens and administration of an antiparasitic product. At the time cattle were received at feedlots and processed, ears were palpated, and any implants that were located were excised. Rectal palpation or ultrasound evaluation of heifers was performed to facilitate identifi cation and exclusion of pregnant animals.
Experimental treatments were administered on d 0 with a Synovex SX-10 implant gun (Zoetis LLC). In cattle treated with EB, TBA, or EB/TBA, implants were placed subcutaneously in the middle one-third of the posterior aspect of the pinna of the ear. Treatment of SC cattle involved subcutaneous penetration in the middle one-third of the posterior aspect of the pinna of the ear with the stylet of a Synovex SX-10 gun that did not contain implants. Dry ears were implanted without cleaning. Ears that were wet or contaminated with manure and/ or mud were scrubbed with chlorhexidine (Nolvasan; Zoetis LLC) before implanting. Stylets of implant guns were disinfected in a chlorhexidine solution after treating each animal. Ears were palpated on d 35 to document implant presence and local reactions at implant sites.
Study pens at ID, TX, and CO were outdoors, naturally lighted and ventilated, had no shade, and had dirt surfaces. Pens at KS were outdoors and naturally lighted and ventilated, but shade was provided by a corrugated steel roof that covered approximately 50% of each pen, and pens had concrete fl oors. Adjustment of cattle to fi nal feedlot diets began during the pretreatment acclimation period. After administration of treatments, cattle were fed diets (Table 1) once daily in fence line feed bunks with the goal to provide ad libitum access to feed. Water was available ad libitum from automatic waterers. No other growth promoters or feed additives (i.e., ionophores, in-feed antibiotics, or melengestrol acetate) were administered.
Full BW of individual heifers were measured once 2 to 3 d before treatment, on d 0, 35, and 70, and on 2 d consecutively before cattle were harvested. The function of animal scales was verifi ed using reference weights each time cattle were weighed. Initial BW of each animal was computed as the mean of the fi rst pretreatment BW and the d 0 BW, and the fi nal BW was computed as the average of values obtained on the 2 d before harvest. For cattle that completed at least 35 d but did not complete the study, the fi nal BW was the last interim BW measured before the animal left the study. The ADG for each pen of cattle was computed as the total BW gained by the pen of cattle from the time of treatment until the fi nal BW was measured, divided by the number of animal-days for the pen.
Heifers were observed daily for potential adverse reactions or health abnormalities, and observations were documented by personnel masked to experimental treatments. Adverse events (AE) were defi ned as any unfavorable or unintended observations in any animal, and all were documented, whether or not they were considered related to experimental treatments. All therapeutic treatments were documented from the time that experimental treatments were administered through study completion.
On the basis of visual observation by persons masked to treatment, blocks of cattle were eligible for harvest when it was determined that at least 60% of animals were likely to grade Choice or greater. On this basis, the average number of days fed for heifers at ID, CO, TX, and KS were 109, 108, 106, and 126 d after treatment, respectively. Cattle were harvested at commercial abattoirs, and all carcass data were collected by personnel from the Beef Carcass Research Center at West Texas A&M University, Canyon, TX, who were masked to treatments. Livers were scored according to a written standard operating procedure (A-= minor abscess; A = few minor abscess(es) and/or moderate abscess(es); A+ = severe abscess(es); A+OP = severe ruptured abscess(es); A+AD = severe abscess(es) with adhesions; A+AD OP = severe ruptured abscess(es) with adhesions; others included cirrhosis, fl ukes, telangiectasias, and contamination. Carcass data directly observed or derived from observed raw data included HCW, estimated percentage of KPH, LM area using the reverse blot image technique described by Martin (1991) , and subcutaneous 12th-rib fat depth using a USDA preliminary yield grade ruler (USDA, 1997) and then adjusted to correct for atypical fat distribution. Marbling was documented to the nearest tenth of a degree (USDA, 1997) by a single evaluator, and then degrees were converted to numeric marbling values where, for example, marbling of Small 00 had a corresponding numeric marbling value of 400 and marbling of Small 90 had a numerical marbling value of 490. An overall maturity score was determined for each carcass on the basis of USDA standards (USDA, 1997). An overall maturity score was determined for each carcass on the basis of USDA standards (USDA, 1997). A fi nal USDA quality grade (QG) was assigned on the basis of marbling degree, lean color score, and overall maturity. Yield grade was computed using a standard formula (USDA, 1997), and dressing percentage was computed as (HCW/fi nal BW) × 100.
Statistical Analysis
Statistical analyses of normally distributed response variables were performed by ANOVA (SAS Inst. Inc., Cary, NC). Pen was the experimental unit, and PROC MIXED procedures of SAS were used to evaluate fi xed effects of treatment and random effects of site, block within site, and treatment by site interactions. The overall treatment effect was tested at a P-value of 0.05 against the site × treatment interaction. Treatment least squares means (LSM) were calculated for each group, and mean comparisons were performed only when the main effect of treatment was signifi cant. For ADG and G:F summarized over the complete duration of the study, pairwise comparisons of LSM for EB/TBA vs. SC, EB, or TBA were performed by the 1-sided Student's t test at the 5% level of signifi cance. In addition, pairwise comparisons of EB or TBA were compared with SC by the 1-sided Student's t test at the 5% level of signifi cance. The use of the 1-sided Student's t test to evaluate ADG and G:F between d 0 and the end of the study was established a priori and was justifi ed because over the entire duration of the study implant treatments were expected to increase these measures relative to SC and EB/TBA was expected to increase these measures compared with EB or TBA. Finally, EB and TBA were compared by the 2-sided Student's t test at the 5% level of significance. Other normally distributed data, including fi nal DMI; initial, interim, and fi nal BW; interim ADG, DMI, and G:F data, and most carcass data, were analyzed by techniques described above, but pairwise comparison of treatment LSM were performed by the 2-sided Student's t test at the 5% level of signifi cance.
Each category of lean color score and maturity score was analyzed using generalized linear mixed models assuming a binomial distribution with a logit link function, implemented using the GLIMMIX procedure of SAS. Pen was the experimental unit, and the model evaluated the fi xed effect of treatment and random effects of site, site by treatment interactions, block within site, and residual. Effects of treatment were assessed at a significance level of 0.05.
Using dichotomous frequency tables of QG data (≥ Choice vs. < Choice) or liver score data (normal vs. the total livers condemned due to abscesses), treatment groups were examined for homogeneity by the CochranMantel-Haenszel test (SAS Inst. Inc.), stratifying by block and testing for heterogeneity of odds ratios across strata using the Breslow-Day test of SAS at the 5% level of signifi cance. Proportions of responses in each category of QG or liver score were evaluated by the 2-sided Fisher's exact test at the 5% level of signifi cance to determine if distributions between populations of heifers in each treatment were different.
RESULTS
At 35 d after treatment, implants were located in 99.3% of EB/TBA heifers presented for observation, 99.6% of heifers treated with EB, and 98.7% of heifers treated with TBA (Table 2) . Implants were absent from 453 SC heifers (99.3%), but implants were present in 3 SC heifers, and all 3 were at the ID site. One of these 3 ID heifers contained a single implant pellet, likely from incomplete removal of a preexisting implant during initial processing. In the 2 other animals, EB/TBA implants were likely erroneously administered on d 0. Despite the presence of implants, these 3 SC animals remained in the data set. Of the EB/TBA heifers, the incidence rate of implant site reactions on d 35 was 1.8%; it was 0.9% among EB heifers, 0.4% among TBA heifers, and 0% among the SC heifers. Reactions included evidence of abscesses, fl uid around implants, scar tissue at implant sites, and swelling. The incidence of implant site reactions was consistent with expectations resulting when good preimplantation hygiene procedures are implemented.
Across sites, 1,824 animals were enrolled (456 animals in each treatment group), and 10 heifers were discontinued after treatment (1 SC, 3 EB, 4 TBA, and 2 EB/ TBA; Table 3 ). The weighted average for study duration was 112 d. Average BW of cattle on d 0 were not significantly different among treatments. At the time d 35, d 70, and harvest weights were obtained, SC cattle achieved average BW that were less (P < 0.05) than cattle treated with EB/TBA or TBA but not different than heifers treated with EB. The d 70 and fi nal BW of heifers treated with EB/TBA were greater (P < 0.05) than BW of heifers treated with EB or TBA. Overall, heifers implanted with EB/TBA, EB, or TBA gained 15.2 kg (8.7%), 4.5 kg (2.4%), and 9.4 kg (5.1%), respectively, more BW than SC heifers.
Treatment-by-site interactions on response criteria were not signifi cant (P > 0.05), thus justifying pooling of data across sites. Over the course of the entire study, 2 Mean for SC less than TBA or EB/TBA by the 2-sided t test (P ≤ 0.05).
3 Mean for EB/TBA greater than EB or TBA by the 2-sided t test (P ≤ 0.05).
4 Mean for EB, TBA, or EB/TBA greater than SC by the 1-sided t test (P ≤ 0.05).
5 Mean for EB/TBA greater than EB or TBA by the 1-sided t test (P ≤ 0.05).
6 Mean for EB, TBA, or EB/TBA greater than SC by the 2-sided t test (P ≤ 0.05).
7 Mean for EB different from TBA by the 2-sided t test (P ≤ 0.05). mean ADG by cattle implanted with EB/TBA, EB, or TBA were greater by the 1-sided t test than SC (P ≤ 0.05; Table 3 ). In addition, ADG by EB/TBA cattle was greater than either EB or TBA (P ≤ 0.05). Treatment effects on interim ADG results through 35 d and 70 d were similar to those observed over the entire course of study.
Across treatments, DMI averaged 9.94 kg/d over the complete study and was not infl uenced by treatments (P > 0.05); interim DMI data were similarly not affected by treatments. Interim and fi nal G:F by cattle implanted with EB/TBA, EB, or TBA were greater than for SC (P ≤ 0.05). In addition, G:F for cattle implanted with EB/ TBA was greater than for EB or TBA (P ≤ 0.05). Finally, evaluated over the entire period of study, G:F for cattle treated with EB or TBA were different by the 2-sided t test (P ≤ 0.05). Over the entire period of study, G:F for heifers treated with EB/TBA, EB, or TBA improved 6.5%, 1.9%, and 4.5%, respectively, compared with SC.
Mean HCW from EB/TBA animals was greater (P ≤ 0.05) than for EB, TBA, or SC (Table 4) , and TBA was greater than SC (P ≤ 0.05). Carcasses from EB/ TBA heifers weighed an average of 7.9 kg more than EB, 5.1 kg more than TBA, and 12.1 kg more than SC. Treatment-related effects on KPH, FAT, and yield grade were not detected (P > 0.05). At 86.1 cm 2 , LM area from EB/TBA heifers was greater (P ≤ 0.05) than in other treatments. In addition, although not different from each other, LM areas for cattle treated with either EB or TBA were greater (P ≤ 0.05) than SC.
Lean color score distributions, although not presented in tabular form, were evaluated to assess treatment effects and were not different between treatments (P > 0.05). Across treatments, color scores of 5 and 6 accounted for about 96% of carcasses, with approximately 31% of carcasses with lean color scores of 5 and approximately 65% with lean color scores of 6. Proportions of carcasses classifi ed as dark cutters (combined proportions with color scores of 7 to 9) were not affected by treatment (P > 0.05).
Although overall maturity scores for carcasses are not presented in tabular form, across the 4 treatments, 99.4% of cattle received overall maturity scores of A, 0.6% were B maturity, and 0.3% were C maturity. For A and B maturity scores treatment effects were not significant (P > 0.05), and for C maturity there were inadequate data to allow for convergence of the statistical model.
Marbling scores were infl uenced by treatment, with the mean marbling score from EB/TBA cattle being lower (P ≤ 0.05) than for all other treatments; treatment means for EB, TBA, and SC were not different from each other. Distributions of carcasses into QG categories of ≥ Choice or < Choice were not affected by treatment (P ≥ 0.05). Of carcasses assigned a QG, proportions ≥ Choice for EB/TBA, EB, TBA, and SC were 61.4%, 68.7%, 64.1%, and 66.0%, respectively. Although the difference was small, dressing percentage was greater for heifers treated with EB/TBA than SC (P = 0.004); dressing percentages for EB and TBA were not different from each other, nor were they different from cattle treated with EB/TBA or SC (P > 0.05).
Fisher's exact test showed that distributions of liver scores into categories of either normal or abscessed were signifi cantly affected by treatment (Table 5) . Treatment effects on liver scores were evaluated by comparing only normal livers and those condemned due to liver abscesses (excluding data from animals with livers condemned due to fl ukes, cirrhosis, telangiectasis, or contamination). Proportions of livers classifi ed as normal from animals treated with EB/TBA, EB, TBA, and SC were 70.5%, 61.2%, 70.0%, and 68.1%, respectively. Pairwise comparisons of treatment proportions by the Fisher's exact test showed that EB and SC were different (P ≤ 0.002) and that EB and TBA were different (P ≤ 0.03). These differences were not expected, biological explanations are not apparent to the authors, and we therefore conclude that they likely represent spurious observations. Pairwise comparisons of SC, EB, and TBA to EB/TBA revealed no treatment differences (P > 0.05).
Although not summarized in tabular form, the number of animals treated with EB/TBA, EB, TBA, and SC that experienced at least 1 AE were 14, 18, 16, and 20, 1 SC = sham-implanted control; EB = 14 mg estradiol benzoate per animal; TBA = 100 mg trenbolone acetate per animal; EB/TBA = 14 mg estradiol benzoate and 100 mg trenbolone acetate per animal (Zoetis LLC, Madison, NJ).
2 Small 00 = 400, Modest 90 = 590.
respectively. The most frequently cited AE were attributed to musculoskeletal disorders (n = 27), respiratory tract disorders (n = 15), skin and appendages disorders (n = 11), digestive tract disorders (n = 7), and undifferentiated systemic disorders (n = 6). The nature of AE documented was consistent with common abnormalities in feedlot cattle. A total of 39 of 1,824 cattle enrolled in the study (2.1%) received at least 1 concurrent treatment. Of heifers treated with EB/TBA, EB, TBA, or SC, the number that received at least 1 concurrent medical treatment after experimental treatment was 10, 10, 9, and 10, respectively, and the frequency was comparable between experimental treatments.
DISCUSSION
Studies evaluating combinations of estradiol and the synthetic androgen TBA have been reported in the literature for almost 40 yr (Grandadam et al., 1975) . Anabolic implantation of feedlot and grazing cattle, typically with a combination of estrogenic and androgenic compounds, is common practice in North American livestock production (Bartle et al., 1992; National Animal Health Monitoring System, 2000; Duckett and Andrae 2001) . It is well established that anabolic implants enhance weight gain but have the potential to reduce carcass QG because of decreased intramuscular fat deposition (Herschler et al., 1995; Cleale et al., 1999; Roeber et al., 2000; Duckett and Andrae 2001; Montgomery et al., 2001; Boles et al., 2009 ). Thus, a continuing challenge for producers is to utilize an implant strategy that improves production while maintaining acceptable carcass quality. Although aggressive implantation using high-potency anabolic compounds can result in signifi cant reductions in QG vs. nonimplantation, lower-dose implants potentially minimize quality losses while still achieving improvements in production. Previous studies that evaluated responses of cattle to implants of varying potency have shown that lower-dose formulations are often associated with better carcass quality while achieving productivity comparable with greater-potency implants (Schneider et al., 2007; Folmer et al., 2009) . A central fi nding of our study was that a moderate-dose implant containing 14 mg of EB and 100 mg of TBA (EB/TBA) signifi cantly improved ADG and G:F in heifers compared with other treatments, concurrently with a nonsignifi cant reduction in percentage of carcasses grading ≥ Choice (61.4% vs. 66.0% for SC carcasses, 64.1% for TBA carcasses, and 68.8% for EB carcasses). For example, at the ID test site, 73.9% of EB/TBA-implanted heifers had a carcass grade ≥ Choice, a percentage that was not signifi cantly different from any other ID treatment group. This site-specifi c outcome indicates that EB/TBA-implanted heifers have the potential for minimal loss of QG while achieving signifi cantly greater production values vs. nonimplanted cattle.
Implants containing combinations of 14 mg EB and 100 mg TBA or 28 mg EB and 200 mg TBA were previously evaluated in a multisite, 140-d trial in heifers with initial BW of 246 to 263 kg (Herschler et al., 1995) . In the work by Herschler et al. (1995) , heifers given a moderate-dose implant containing 14 mg EB and 100 mg TBA had mean ADG and G:F ratios that were statistically equivalent to those of heifers given implants containing 28 mg EB and 200 mg TBA. Herschler et al. (1995) also determined that heifers given implants containing 14 mg EB and 100 mg TBA had a 6.6% reduction in marbling scores vs. nonimplanted controls, whereas heifers treated with 28 mg EB and 200 mg TBA yielded a 10.1% decrease in marbling scores vs. nonimplanted controls. In the work by Herschler et al. (1995) , proportions of carcasses with QG of Choice from heifers treated with no implant, 14 mg EB and 100 mg TBA, or 28 mg EB and 200 mg TBA were 76%, 63%, and 52%, respectively. Under the conditions of their study, Herschler et al. (1995) determined that the value of carcasses from heifers treated with 14 mg EB and 100 mg TBA was greater than the value of carcasses from heifers treated with 28 mg EB and 200 mg TBA, largely due to comparable effects of treatments on mean HCW but the lesser effect of implants containing 14 mg EB and 100 mg TBA on QG. Our study was intended to build on 2 SC = sham-implanted control; EB = 14 mg estradiol benzoate per animal; TBA = 100 mg trenbolone acetate per animal; EB/TBA = 14 mg estradiol benzoate and 100 mg trenbolone acetate per animal (Zoetis LLC, Madison, NJ).
3 A-, minor abscess; A, few minor abscess(es) and/or moderate abscess(es); A+, severe abscess(es); A+OP, severe ruptured abscess(es); A+AD, severe abscess(es) with adhesions; A+AD OP, severe ruptured abscess(es) with adhesions. this earlier work and was designed to confi rm the performance benefi ts in heifers treated with EB/TBA vs. EB or TBA alone at the dose levels specifi ed above.
Results confi rmed that EB and the highly potent, synthetic androgen TBA have additive effects whereby calves implanted with EB/TBA responded with improved ADG and G:F compared with calves implanted with either anabolic agent given alone or compared with nonimplanted SC calves. The additive responses to EB and TBA corroborate earlier studies of a high-dose implant containing 28 mg EB and 200 mg TBA (Synovex Plus; Zoetis LLC), which was approved in the United States for use in feedlot steers and heifers (Bouffault and Willemart, 1983; Cleale et al., 1999) . Not only do EB and TBA have additive effects, but when combined in a single implant, they have been shown to maintain a greater plasma concentration of estradiol and prolong BW gain beyond what occurs when EB is given alone (Heitzman et al., 1981) .
The synergistic effect of estrogens and androgens is likely related to different mechanisms of action (Hayden et al., 1992) . Bovine skeletal muscle contains estrogenand androgen-specifi c receptors (Sauerwein and Meyer, 1989) . Studies with beef cattle indicate that the growth response to administration of estrogenic compounds is related to stimulation of pituitary GH secretion (Grigsby and Trenkle, 1986) and subsequent stimulation of IGF-1 release (Johnson et al., 1996) . Growth hormone and IGF-1 both enhance growth performance. The mechanism of action of trenbolone does not appear to be related to effects on the somatotropic axis (Hayden et al., 1992; Pampusch et al., 2008) . Rather, TBA has been implicated in the synthesis of cortisol, which indirectly controls muscle protein degradation (Hayden et al., 1992; Isaacson et al., 1993; Bryant et al., 2010) . In one study, for example, calves implanted with a 300 mg dose of TBA had signifi cantly less (P < 0.01) serum cortisol concentrations vs. nonimplanted control calves or calves implanted with 24 mg of EB (Hayden et al., 1992) . The investigators speculated that reduced cortisol synthesis may be due to increased production of cortisol-binding globulin. The net effect is to increase protein accretion in skeletal muscle by preempting protein degradation caused by antianabolic effects of cortisol. These in vivo results were later affi rmed by in vitro assays of cortisol release by adrenal cells obtained at necropsy from steers given anabolic implants. In this work, TBA decreased cortisol production by 20% to 30% in adrenal cell cultures (Isaacson et al., 1993) . Collectively, these fi ndings acquire relevance in view of our results confi rming that a combination implant produces a greater response than either anabolic component given alone, an outcome that is explained by a dual mechanism of action.
Finishing weight remains the principal driver of profitability. However, the option of using intermediate-dose implants is appealing for producers who practice gridbased marketing, where production is weighed against marbling and QG to obtain a premium price. A moderate implantation strategy that balances production against carcass quality can be particularly useful in circumstances that increase cost of BW gain, such as when feed costs are high, during adverse environmental conditions, or when calves with less favorable genetic potential are being fed. The results of our study indicate that administration of a moderate-dose implant containing 14 mg of EB and 100 mg of TBA at the outset of the feeding period is a viable approach for grade-conscious feeders who also want to achieve optimum production gains.
